Venatorx Pharmaceuticals has been awarded an NIH R01 Grant for novel approaches to address biodefense-related infections. The company may receive up to $6M of funding under the grant.
Venatorx Pharmaceuticals has been awarded an NIH R01 Grant for novel approaches to address biodefense-related infections. The company may receive up to $6M of funding under the grant.
| You are using a browser that is not supported. Please consider changing your browser |